Hope restored: The critical role that Minimal Residual Disease can play in blood cancer patient care

Read Post
Logo for Adaptive Biotechnologies
Drug Discovery

Antibody Therapeutics

Identifying Antibodies for Therapeutic Use

Adaptive’s high-throughput antibody discovery process enables rapid identification and selection of potent, naturally occurring, entirely human antibodies for clinical development and commercialization.

Differentiators of Adaptive’s Approach

Two-tone-icon--Versatility-

Versatility

  • Use B cells from human blood
  • Sourced from humanized mice
Two-tone-icon--Safety-01

Safety

  • De-risked for manufacturing and developability
  • Likely favorable safety profile
Two-tone-icon--Selection

High-throughput, high sensitivity

  • Hundreds of thousands of antibodies at a time
  • Select likely winners using bioinformatics
  • Accurate BCR heavy/light pairs at unprecedented scale
  • Screen for natural human antibodies
Two-tone-icon--T-Cell

Best clinical candidate selection

  • Entire B-cell receptors (BCR) repertoire interrogated
  • Well-characterized, naturally optimized antibodies
  • Support rational monoclonal antibody combinations

Developing Therapeutic Antibodies Against SARS-CoV-2

Neutralizing antibodies defend healthy cells by blocking the biological function of an invading virus. 

Adaptive has identified and characterized ultra-potent, neutralizing antibodies that bind to different parts of the SARS-CoV-2 virus and can be considered for development to treat COVID-19.